RxDoctor Payments Data

Beth Covington, NP

Family · Hanover, PANPI 1023539095

Payments from drug & device makers

$1,456in general payments, 2019–2025

Across 57 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$427
  • Otsuka America Pharmaceutical, Inc.$345
  • Amgen$288
  • Phathom Pharmaceuticals, Inc.$92
  • Exact Sciences$85
  • Lilly USA, LLC$63
  • plus $155 from 4 others

What the payments were for

  • Food & beverage$1,456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,456 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,616
Medicare patients
221
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban184$123,516
IngrezzaValbenazine Tosylate16$93,653
TrulicityDulaglutide37$44,285
JardianceEmpagliflozin50$39,572
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$29,771
MounjaroTirzepatide16$24,368
XareltoRivaroxaban38$22,229
RybelsusSemaglutide12$20,603
EntrestoSacubitril/Valsartan22$18,528
GemtesaVibegron31$15,554
OzempicSemaglutide14$14,594
Breo ElliptaFluticasone/Vilanterol26$10,633
Spiriva HandihalerTiotropium Bromide13$10,253
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,762
LinzessLinaclotide11$6,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$63$68,65353 claims
Sumitomo Pharma America, Inc.Gemtesa$46$15,55431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →